Sensus Healthcare, Inc. (SRTS) Announces Exclusive US Distribution Agreement with Mattioli for TransDermal Infusion System

Go back to Sensus Healthcare, Inc. (SRTS) Announces Exclusive US Distribution Agreement with Mattioli for TransDermal Infusion System

Sensus Healthcare Signs Exclusive U.S. Distribution Agreement with Mattioli Eng. Italia for its TransDermal Infusion System

December 1, 2021 8:30 AM EST

BOCA RATON, Fla, Dec. 01, 2021 (GLOBE NEWSWIRE) -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in highly effective, non-invasive, minimally-invasive and cost-effective treatments for oncological and non-oncological conditions, announces the signing of an exclusive U.S. distribution agreement with Mattioli Eng. Italia S.P.A. for its TransDermal Infusion System non-invasive drug delivery system.  Sensus plans to begin marketing this System to dermatologists nationwide beginning immediately.

The TransDermal Infusion System is cleared by the U.S. Food and Drug Administration (FDA) for the local administration of ionic... More